ELITE PHARMACEUTICALS INC /NV/ Balance Sheet
ELTP|14 years of annual SEC 10-K data (FY2011-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 14 fiscal years. All figures from audited SEC 10-K filings.
ELITE PHARMACEUTICALS INC /NV/ had $96M in total assets and $54M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.19 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | - | $7.1M | $7.8M | $8.5M | $3.2M | $1.1M | $2.3M | $7.2M | $10.6M | $11.5M | $7.5M | $6.9M | $668.4K | $1.8M |
| Accounts Receivable | $29.2M | $19.5M | $3.1M | $3.1M | $3.5M | $4.1M | $1.3M | $675.9K | $934.1K | $1.5M | $1.4M | $732.1K | $396.8K | $571.7K |
| Inventory | $16.2M | $12.9M | $9.6M | $6.7M | $5.0M | $4.1M | $4.5M | $4.9M | $6.4M | $3.3M | $3.0M | $1.9M | $304.9K | $616.4K |
| Current Assets | $57.7M | $40.0M | $21.5M | $18.9M | $12.2M | $10.3M | $8.9M | $13.7M | $18.4M | $16.7M | $12.3M | $9.9M | $1.5M | $3.1M |
| PP&E (Net) | $10.3M | $10.2M | $10.4M | $6.0M | $6.6M | $7.2M | $8.4M | $9.0M | $9.0M | $8.1M | $6.4M | $4.2M | $4.3M | $4.1M |
| Total Assets | $96.4M | $83.7M | $40.9M | $35.1M | $26.2M | $25.0M | $24.4M | $30.9M | $34.3M | $31.7M | $25.9M | $24.3M | $10.3M | $11.8M |
| Current Liabilities | $11.8M | $13.0M | $7.8M | $6.7M | $5.8M | $8.6M | $6.9M | $5.1M | $3.3M | $4.6M | $5.1M | $6.2M | $4.5M | $4.7M |
| Total Debt | - | - | - | $1.4M | $1.5M | $1.6M | - | - | - | - | - | - | - | - |
| Shareholders' Equity | $53.5M | $57.6M | $29.0M | $25.2M | $16.2M | $10.7M | -$2.5M | $4.6M | $25.7M | -$33.1M | -$34.7M | -$81.2M | -$15.0M | -$17.9M |